Abrocitinib induction treatment was effective for moderate-to-severe AD, with most responders continuing treatment without a flare, according to a study published in the Journal of the American Academy of Dermatology. Andrew Blauvett, MD, MBA, and colleagues randomized patients with moderate-to-severe AD—who were responders to open-label abrocitinib 200 mg monotherapy for 12 weeks—in a 1:1:1 ratio to 40 weeks of blinded placebo or abrocitinib 200 or 100 mg. Rescue treatment with abrocitinib 200 mg plus topical therapy was prescribed to those who experienced a flare. Rates of flare probability were 18.9% and 42.6% with abrocitinib 200 mg and 100 mg, respectively, compared with 80.9% with placebo. Investigator global assessment 0/1 response was regained by 36.6%, 58.8%, and 81.6% of patients with flare who received abrocitinib 200 mg, abrocitinib 100 mg, and placebo, respectively; with rescue treatment, 55.0%, 74.5%, and 91.8% of these respective groups regained eczema area and severity index response. Adverse events during maintenance were experienced by 63.2% of patients receiving abrocitinib 200 mg and 54.0% of those receiving abrocitinib 100 mg.

Author